Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 in ART-treated HIV
NCT04808908Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in human immunodeficiency virus infection (HIV), sponsored by University of Minnesota. Primary endpoint: Safety (Adverse Event Rate) at 6 months. Started Apr 2021; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04808908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808908.